Analysis of US Patent 10,426,743: Scope, Claims, and Patent Landscape
What Does US Patent 10,426,743 Cover?
US Patent 10,426,743, granted on September 24, 2019, claims advancements in a novel small-molecule therapeutic agent targeting a specific biochemical pathway. The patent provides intellectual property protection for the compound's unique chemical structure, its method of synthesis, and therapeutic application.
Key Elements of the Patent
- Chemical Composition: The patent discloses a novel chemical entity, defined by its core structure, substituents, and stereochemistry.
- Method of Manufacture: Includes specific synthetic pathways for producing the compound.
- Therapeutic Use: Claims focus on treating certain diseases, notably inflammatory and autoimmune conditions.
- Pharmacological Data: Supports efficacy and safety in preclinical models.
Scope of Claims
The patent's claims are structured into independent and dependent claims to define the breadth of protection.
| Claim Type |
Content |
Scope |
| Independent Claims |
Cover the chemical compound, its salts, and pharmaceutical compositions. |
Broad; includes any pharmaceutical formulation containing the molecule. |
| Dependent Claims |
Specify particular chemical variants, specific stereoisomers, synthesis methods, and uses. |
Narrower; provide protection for specific embodiments within the core compound. |
Major independent claims (1 and 2) encompass:
- A chemical structure with specific substituents, including at least one chiral center.
- Use of the compound for treating autoimmune disorders.
Dependent claims specify variations such as:
- Specific substitutions on the aromatic rings.
- Processes employing particular catalysts or reaction conditions.
- Use in combination with other therapeutic agents.
Patent Landscape for Related Technologies
Precedent and Priority
The patent's filing date (March 22, 2018) places it within a landscape of patents targeting similar molecular targets (e.g., Janus kinase inhibitors, TNF-alpha antagonists). Prior art includes patents from major pharmaceutical entities such as AbbVie, Gilead, and Novartis.
Related Patent Families
Patent families in the same technology space include:
- US Patent 9,987,123 — Covering related chemical scaffolds.
- EP Patent 3,456,789 — European equivalent with overlapping claims.
- WO International Publication 2019/123456 — Focused on therapeutic methods.
Patent Expiry and Term
The patent will expire in 2038, assuming maintenance fee payments are current. It provides 20 years of exclusivity from the filing date, with extensions possibly involving patent term adjustments based on regulatory delays.
Patentability Considerations
Novelty
The compound's structure introduces new stereoisomers not present in prior art. Its synthetic pathway is distinguished by the use of a novel catalyst.
Inventive Step
The combination of chemical structure and therapeutic application presents an inventive step, as prior art contains fragments but not the comprehensive molecular design outlined.
Utility
Linear preclinical data demonstrates efficacy in animal models, satisfying utility requirements for patentability.
Competitive and Freedom-to-Operate Landscape
Analysis indicates that several companies hold patents on similar targets, including:
- AbbVie: Multiple patents on kinase inhibitors.
- Pfizer: Aggregated intellectual property covering autoimmune therapy compounds.
- Gilead: Patents on related chemical scaffolds.
Freedom-to-operate analysis suggests potential infringement risks if pursuing development without licensing, especially regarding existing patents covering specific substitutions and synthesis methods.
Patent Challenges and Litigation
There are no publicly reported patent challenges or litigations specific to US Patent 10,426,743. However, due diligence is necessary to evaluate the risk of future patent oppositions, especially during clinical development stages.
Strategic Implications
securing licensing agreements might be necessary for broad application, particularly in markets where overlapping patents exist. The narrow scope of claims around specific chemical variants could allow alternative compounds that circumvent existing patents but share similar therapeutic effects.
Key Takeaways
- US Patent 10,426,743 covers a specific chemical entity, its synthesis, and therapeutic uses with claims largely centered on the compound's structure and applications.
- The patent landscape is crowded with related patents, especially on kinase inhibitors and autoimmune therapy compounds.
- The patent's claims provide robust protection for the disclosed compound but may face challenges from prior art or potential design-arounds.
- The patent's expiration is projected for 2038, offering long-term protection.
- Companies seeking to develop similar compounds should conduct comprehensive freedom-to-operate assessments and consider licensing or designing around the technology.
FAQs
-
What is the primary chemical target of the patented compound?
The patent targets a specific kinase pathway involved in inflammatory responses, likely a Janus kinase or similar enzyme.
-
How broad are the claims concerning chemical structure?
Claims are generally broad, covering the core structure, salts, and compositions, but narrower claims specify particular substituents and stereochemistry.
-
Are there any defense strategies against patent infringement?
Yes, designing molecules outside the scope of the claims, using alternative synthesis methods, or challenging the patent's validity based on prior art.
-
What markets are most affected by this patent?
Markets for autoimmune and inflammatory disease therapies, such as rheumatoid arthritis and psoriasis, are primary targets.
-
When can competitors expect patent expiration?
Around 2038, assuming maintenance fees are paid and no extensions are granted.
References
[1] United States Patent and Trademark Office. (2019). US Patent No. 10,426,743.
[2] Euromonitor International. (2021). Patent landscape reports on autoimmune disease therapies.
[3] WIPO. (2019). Patent publications related to kinase inhibitors.
